Claims for Patent: 10,300,078

Summary for Patent: 10,300,078

Title:	Stabilized modified release vitamin D formulation and method of administering same
Abstract:	A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
Inventor(s):	White; Jay A. (Newmarket, CA), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy A. (Mississauga, CA), Melnick; Joel Z. (Miami, FL)
Assignee:	OPKO IRELAND GLOBAL HOLDINGS, LTD. (Grand Cayman, KY)
Application Number:	15/990,354
Patent Claims:	1. A stabilized formulation for extended release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation, the formulation comprising a mixture of: one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 in an extended release lipophilic matrix, the lipophilic matrix further comprising a cellulosic stabilizing agent to stabilize the matrix against changes in dissolution release characteristics over time; wherein the cellulosic stabilizing agent is a cellulose ether and is present in an amount of about 5 wt % to about 30 wt % of the stabilized formulation; wherein the formulation is characterized by providing a mean baseline-adjusted in vivo C.sub.max per microgram of 25-hydroxyvitamin D administered to humans in a range of about 0.0133 ng/mL to about 0.04 ng/mL. 2. The stabilized formulation of claim 1, wherein the formulation, following storage for 3 months at 25.degree. C. and 60% RH, provides a C.sub.max within 80% to 125% of the mean of product before storage. 3. The stabilized formulation of claim 1, wherein the lipophilic matrix comprises a wax. 4. The stabilized formulation of claim 3, wherein the lipophilic matrix comprises paraffin wax. 5. The stabilized formulation according to claim 1, further comprising an emulsifier. 6. The stabilized formulation according to claim 5, wherein the emulsifier comprises glycerol monostearate. 7. The stabilized formulation according to claim 1, further comprising an absorption enhancer. 8. The stabilized formulation according to claim 7, wherein the absorption enhancer is a mixture of lauroyl macrogolglycerides and lauroyl polyoxylglycerides. 9. The stabilized formulation according to claim 1, further comprising an oily vehicle. 10. The stabilized formulation according to claim 9, wherein the oily vehicle comprises mineral oil. 11. The stabilized formulation according to claim 1, wherein the lipophilic matrix comprises a wax, an oil, an emulsifier, and an absorption enhancer. 12. The stabilized formulation according to claim 1, wherein the formulation comprises about 20 wt % paraffin, about 20 wt % to about 25 wt % glycerol monostearate, about 10 wt % a mixture of lauroyl macrogolglycerides and lauroyl polyoxylglycerides, about 30 wt % to about 35 wt % mineral oil, and about 10 wt % to about 15 wt % hydroxyl propyl methylcellulose. 13. The stabilized formulation according to claim 12, wherein the vitamin D compound comprises 25-hydroxyvitamin D.sub.3. 14. The stabilized formulation according to claim 1, wherein the cellulose ether comprises one or more of methylcellulose, hydroxyl propyl methylcellulose, hydroxyl ethyl methylcellulose, hydroxyl ethyl cellulose, and hydroxyl propyl cellulose. 15. The stabilized formulation according to claim 14, wherein the cellulose ether comprises hydroxyl propyl methylcellulose. 16. An extended release dosage form in the form of a capsule, tablet, sachet, or dragee comprising a stabilized formulation according to claim 1. 17. A stabilized formulation for extended release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation, the formulation comprising a mixture of: one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 in an extended release lipophilic matrix, the lipophilic matrix further comprising a cellulosic stabilizing agent to stabilize the matrix against changes in dissolution release characteristics over time; wherein the cellulosic stabilizing agent is a cellulose ether and is present in an amount of about 5 wt % to about 30 wt % of the stabilized formulation; wherein the formulation, when administered to adult humans having CKD Stage 3 with secondary hyperparathyroidism and vitamin D insufficiency, and at daily oral doses of 30 mcg, is characterized by providing a baseline-adjusted AUC.sub.0-6 wk of the administered vitamin D compound having a mean of about 700 ngd/mL. 18. A stabilized formulation for extended release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation, the formulation comprising a mixture of: one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 in an extended release lipophilic matrix, the lipophilic matrix further comprising a cellulosic stabilizing agent to stabilize the matrix against changes in dissolution release characteristics over time; wherein the cellulosic stabilizing agent is a cellulose ether and is present in an amount of about 5 wt % to about 30 wt % of the stabilized formulation; wherein the formulation, when administered to adult humans having CKD Stage 3 with secondary hyperparathyroidism and vitamin D insufficiency, and at daily oral doses of 60 mcg, is characterized by providing a baseline-adjusted AUC.sub.0-6 wk of the administered vitamin D compound having a mean of about 1500 ngd/mL. 19. A stabilized formulation for extended release of a vitamin D compound in the gastrointestinal tract of a subject which ingests the formulation, the formulation comprising a mixture of: one or both of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 in an extended release lipophilic matrix, the lipophilic matrix further comprising a cellulosic stabilizing agent to stabilize the matrix against changes in dissolution release characteristics over time; wherein the cellulosic stabilizing agent is a cellulose ether and is present in an amount of about 5 wt % to about 30 wt % of the stabilized formulation; wherein the formulation, when administered to adult humans having CKD Stage 3 with secondary hyperparathyroidism and vitamin D insufficiency, and at daily oral doses of 90 mcg, is characterized by providing a baseline-adjusted AUC.sub.0-6 wk of the administered vitamin D compound having a mean of about 2100 ngd/mL. 20. The stabilized formulation of claim 17, wherein the formulation comprises 30 mcg 25-hydroxyvitamin D.sub.3. 21. The stabilized formulation of claim 17, wherein the lipophilic matrix comprises a wax. 22. The stabilized formulation of claim 21, wherein the lipophilic matrix comprises paraffin wax. 23. The stabilized formulation according to claim 17, further comprising an emulsifier. 24. The stabilized formulation according to claim 17, wherein the lipophilic matrix comprises a wax, an oil, an emulsifier, and an absorption enhancer. 25. The stabilized formulation according to claim 17, wherein the formulation comprises about 20 wt % paraffin, about 20 wt % to about 25 wt % glycerol monostearate, about 10 wt % a mixture of lauroyl macrogolglycerides and lauroyl polyoxylglycerides, about 30 wt % to about 35 wt % mineral oil, and about 10 wt % to about 15 wt % hydroxyl propyl methylcellulose. 26. The stabilized formulation according to claim 25, wherein the vitamin D compound comprises 25-hydroxyvitamin D.sub.3. 27. The stabilized formulation according to claim 17, wherein the cellulose ether comprises one or more of methylcellulose, hydroxyl propyl methylcellulose, hydroxyl ethyl methylcellulose, hydroxyl ethyl cellulose, and hydroxyl propyl cellulose. 28. The stabilized formulation according to claim 27, wherein the cellulose ether comprises hydroxyl propyl methylcellulose.